title: Why, why, why de-lupus (does so badly in clinical trials).
authors.affiliation: a Centre for Rheumatology, Department of Medicine , University College London , London , UK.
authors.forename: David A
authors.initials: DA
authors.lastname: Isenberg
authors.affiliation: b Clinical Pharmacology Research Program , Oklahoma Medical Research Foundation , Oklahoma City , OK , USA.
authors.forename: Joan T
authors.initials: JT
authors.lastname: Merrill
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination / Q000379:methods / Q000639:trends; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D011993:Recombinant Fusion Proteins; C448700:epratuzumab; D000069283:Rituximab; C524618:TACI receptor-IgG Fc fragment fusion protein; C568334:sifalimumab